Michael Heinrich is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd
Portland, OR 972393011
Telephone
503-494-6594Registry record last updated 8 Jul 2007.
Clinical trials
- Potential Benefits of Black Seed Oil Supplementation on Asthma Inflammation and Outcomes
Sponsor: University College, London
- Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene
Sponsor: Arog Pharmaceuticals, Inc.
- Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Sponsor: Novartis Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Deciphera Pharmaceuticals Inc.Program year20256 payments
- GlaxoSmithKline, LLC.Program year20252 payments
- Deciphera Pharmaceuticals Inc.Program year202412 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
61%Kinase inhibitor53.9%Imatinib Mesylate49%Sunitinib Malate25%Gleevec20%Ayvakit6%Part D<11 patientsBCR-ABL tyrosine kinase inhibitors7%Scemblix100%Part D<11 patientsMetabolism & gastrointestinal
19.9%Serotonin-3 Receptor Antagonist12.4%Ondansetron Odt100%Part D≥16 patientsPotassium supplement3.9%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Cardiovascular
11.8%Loop diuretic4.5%Furosemide100%Part D<11 patientsACE inhibitor3.9%Lisinopril100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2009–2025 per NIH RePORTER. The latest:
- Functional profiling of germline SDH variants associated with cancer susceptibility
Portland Va Medical Center
FY2025I01BX005358 - Functional profiling of germline SDH variants associated with cancer susceptibility
Portland Va Medical Center
FY2024I01BX005358 - Functional profiling of germline SDH variants associated with cancer susceptibility
Portland Va Medical Center
FY2023I01BX005358
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”